Active substance
Paricalcitol
- SFDA 7
- US FDA 20
- US price lines 2
- NHS prices 2
- Safety 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Calprime | 5 µ/ml | Solution for injection · Intravenous use | 5 Ampoule | SAR 213.10 | Generic · Prescription | SPIMACO | Valid |
| Paricalcitol Spectro | 5 µ/ml | Solution for injection · Intravenous use | 5 Ampoule | SAR 461.05 | Generic · Prescription | ALTAIF PHARMACEUTICALS COMPANY | Valid |
| Paricalcitol Spectro | 5 µg/ml | Solution for injection · Intravenous use | 5 Ampoule | SAR 230.90 | Generic · Prescription | Spectro Pharma | Valid |
| Thyritol | 5 µ/ml | Solution for injection · Intravenous use | 5 Ampoule | SAR 248.65 | Generic · Prescription | Glenmark Pharmaceuticals Limited | Valid |
| ZEMPLAR 1 mcg Capsule | 1 µg | Capsule · Oral use | 30 Bottle | SAR 419.40 | NCE · Prescription | Abbvie Limited | Valid |
| ZEMPLAR 2 mcg Capsule | 2 µg | Capsule · Oral use | 30 Bottle | SAR 852.45 | NCE · Prescription | Abbvie Limited | Valid |
| ZEMPLAR 5 mcg/ml solution for injection | 5 µ/ml | Solution for injection · Intravenous use | 5 Ampoule | SAR 266.40 | NCE · Prescription | Abbvie Limited | Valid |
Indications — CHI Daman Drug Formulary
CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDERS; HYPERPARATHYRODISM
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ZEMPLAR | 0.005MG/ML (0.005MG/ML); 0.002MG/ML (0.002MG/ML); 0.01MG/2ML (0.005MG/ML) | solution · intravenous | ABBVIE | Prescription | 17 Apr 1998 |
| PARICALCITOL | 0.002MG/ML (0.002MG/ML); 0.005MG/ML (0.005MG/ML); 0.01MG/2ML (0.005MG/ML) | solution · intravenous | SANDOZ | Prescription | 27 Jul 2011 |
| PARICALCITOL | 1MCG; 2MCG; 4MCG | capsule · oral | TEVA PHARMS USA | Prescription | 27 Sep 2013 |
| PARICALCITOL | 1MCG; 2MCG; 4MCG | capsule · oral | BIONPHARMA | Prescription | 27 Mar 2014 |
| PARICALCITOL | 1MCG; 2MCG; 4MCG | capsule · oral | CHARTWELL RX | Prescription | 24 Jun 2014 |
| PARICALCITOL | 1MCG; 2MCG; 4MCG | capsule · oral | RISING | Prescription | 24 Jun 2014 |
| PARICALCITOL | 1MCG; 2MCG; 4MCG | capsule · oral | AMNEAL PHARMS | Prescription | 13 Jan 2016 |
| PARICALCITOL | 1MCG; 2MCG; 4MCG | capsule · oral | AUROBINDO PHARMA LTD | Prescription | 14 Jan 2016 |
| PARICALCITOL | 0.002MG/ML (0.002MG/ML); 0.005MG/ML (0.005MG/ML); 0.01MG/2ML (0.005MG/ML) | solution · intravenous | ACCORD HLTHCARE | Prescription | 4 Feb 2016 |
| PARICALCITOL | 1MCG; 2MCG; 4MCG | capsule · oral | PHARMAZONE | Prescription | 7 Oct 2016 |
| PARICALCITOL | 0.002MG/ML (0.002MG/ML); 0.005MG/ML (0.005MG/ML); 0.01MG/2ML (0.005MG/ML) | solution · intravenous | AMNEAL PHARMS CO | Prescription | 9 Mar 2017 |
| PARICALCITOL | 0.005MG/ML (0.005MG/ML); 0.01MG/2ML (0.005MG/ML) | solution · intravenous | RISING | Prescription | 2 Nov 2017 |
| ZEMPLAR | 1MCG; 2MCG; 4MCG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule · oral | ABBVIE | Discontinued | 26 May 2005 |
| PARICALCITOL | 0.002MG/ML (0.002MG/ML); 0.005MG/ML (0.005MG/ML); 0.01MG/2ML (0.005MG/ML) | solution · intravenous | HOSPIRA | Discontinued | 21 Oct 2014 |
| PARICALCITOL | 0.002MG/ML (0.002MG/ML); 0.005MG/ML (0.005MG/ML); 0.01MG/2ML (0.005MG/ML) | solution · intravenous | HIKMA PHARMS | Discontinued | 18 Nov 2014 |
| PARICALCITOL | 1MCG; 2MCG; 4MCG | capsule · oral | LOTUS PHARM CO LTD | Discontinued | 24 Feb 2016 |
| PARICALCITOL | 0.002MG/ML (0.002MG/ML); 0.005MG/ML (0.005MG/ML); 0.01MG/2ML (0.005MG/ML) | solution · intravenous | CAPLIN | Discontinued | 17 Aug 2016 |
| PARICALCITOL | 0.01MG/2ML (0.005MG/ML) | solution · intravenous | EPIC PHARMA LLC | Discontinued | 16 Oct 2017 |
| PARICALCITOL | 0.002MG/ML (0.002MG/ML) | solution · intravenous | RISING | Discontinued | 2 Nov 2017 |
| PARICALCITOL | 0.002MG/ML (0.002MG/ML); 0.005MG/ML (0.005MG/ML); 0.01MG/2ML (0.005MG/ML) | solution · intravenous | EUGIA PHARMA | Discontinued | 9 Oct 2018 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | PARICALCITOL 1 MCG CAPSULE | $1.27717 | per EA | 23 Sep 2026 |
| US NADAC | PARICALCITOL 2 MCG CAPSULE | $2.58862 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Paricalcitol 1microgram capsules | £69.44 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Paricalcitol 2microgram capsules | £138.88 | 28 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 17 Jun 2026 PARICALCITOL — safety-related labeling change
Labeling sections changed: Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 17 Dec 2019 PARICALCITOL — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 17 Oct 2019 PARICALCITOL — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 18 Oct 2016 ZEMPLAR — safety-related labeling change
Labeling sections changed: Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.